Consultation News and Research

RSS

Updated United States Public Health Service guidelines for management of occupational exposure to HIV

New guidelines from the United States Public Health Service update the recommendations for the management of healthcare personnel with occupational exposure to HIV and use of postexposure prophylaxis.

7 Aug 2013

NSM Insurance Group establishes specialty Behavioral Health, Social Services Unit

NSM Insurance Group announced the establishment of a specialty Behavioral Health, Social Services Unit due to NSM's remarkable growth in this niche over the last 5 years. Bill McKernan, NSM President commented, "It made perfect sense that our Retail clients benefit from the vast expertise NSM has in this space so we created a team comprised of NSM's most experienced Behavioral Health and Social Service Insurance Professionals."

6 Aug 2013

Aetna extends help to its members affected by wildfires burning in Oregon

Aetna is making it easier for members affected by wildfires in Oregon to refill prescriptions and access employee assistance, student assistance and behavioral health programs. The company is also extending claim and appeal filing times, and helping members who have evacuated find care outside their home areas, among other steps.

3 Aug 2013

Bariatric procedures can lead to rapid, safe and permanent weight loss in obese patients

A recent article from CBS News reports on a U.S. government study that found the amount of time a person has been obese can play a significant role in how high their risk of heart disease may be.

1 Aug 2013

Fewer states holding alcohol retailers liable for harms caused by customers who were served illegally

Fewer states are holding alcohol retailers liable for harms caused by customers who were served illegally, according to a new report from researchers at Alcohol Policy Consultations and the Center on Alcohol Marketing and Youth (CAMY) at the Johns Hopkins Bloomberg School of Public Health.

31 Jul 2013

Takeda unbinds Phase 3 study of orteronel in patients with mCRPC that progressed post-chemotherapy

Takeda Pharmaceutical Company Limited ("Takeda") announced today that it has unblinded the ELM-PC 5 Phase 3 study (C21005) of orteronel plus prednisone compared to placebo plus prednisone in patients with metastatic, castration- resistant prostate cancer (mCRPC) that had progressed during or following chemotherapy based on the recommendation of the Independent Data Monitoring Committee (IDMC).

26 Jul 2013

Updated CVD risk audit to help GPs optimise patient management is now available online

With cardiovascular disease (CVD) causing a third of all deaths in Australia, NPS MedicineWise is encouraging GPs to stay up to date with their knowledge about CVD risk assessment and therapy.

26 Jul 2013

Secretary of State for BIS designates LSTM as higher education institution

The Secretary of State for Business, Innovation and Skills (BIS) has, by an Order in Parliament under section 129 of the Education Reform Act 1988, designated the Liverpool School of Tropical Medicine (LSTM) as a higher education institution (HEI) eligible to receive funding direct from the Higher Education Funding Council for England (HEFCE).

25 Jul 2013

Researchers receive $10M March of Dimes grant to study causes of premature birth

Researchers from Dartmouth's Institute for Quantitative Biomedical Sciences (iQBS), the Center for Integrative Biomedical Sciences, and the Center for Genomic Medicine at the Geisel School of Medicine are studying the unknown causes of premature birth, as part of a $10 million March of Dimes grant awarded to a research collaborative of seven U.S. universities and medical centers.

19 Jul 2013

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013

Oncodesign receives AAALAC certification for Dijon-based research center

Oncodesign, a contract research laboratory for the discovery of new anticancer therapies, today announces that its Dijon-based research center has received AAALAC certification.

18 Jul 2013

Vanderbilt research program trains community pediatricians to diagnose autism

A Vanderbilt research program that trains community pediatricians to diagnose autism within their individual practices may lead to more effective treatment of the disorder that now affects an estimated one in 88 children.

12 Jul 2013

PrenaTest can be now performed for high risk pregnancies after ninth week

PrenaTest, Europe's first non-invasive molecular genetic blood test to determine fetal trisomies 13, 18 and 21 in the mother's blood can now be performed for high risk pregnancies after the ninth week (W 9 + D 0).

11 Jul 2013

Pharmacyclics submits ibrutinib NDA to FDA for two B-cell malignancies

Pharmacyclics, Inc. today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for the investigational oral Bruton's tyrosine kinase inhibitor, ibrutinib, for two relapsed/refractory B-cell malignancy indications: mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.

10 Jul 2013

Agreement expands national presence of Cleveland Clinic Laboratories

Cleveland Clinic Laboratories will now be the main provider of specialized testing and diagnostics services for ACL Laboratories, one of the largest hospital system laboratories in the United States.

10 Jul 2013

Saint Luke's Hospital opens Charles & Barbara Duboc Cardio Health & Wellness Center

The Charles & Barbara Duboc Cardio Health & Wellness Center is ushering in a new era for preventive cardiac care at Saint Luke's Hospital.

6 Jul 2013

NanoViricides submits letter of intent to file Orphan Drug Application with EMA for DengueCide

NanoViricides, Inc. announced today that it has submitted its letter of intent to file an Orphan Drug Application with the European Medicines Agency for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.

1 Jul 2013

RUCDR Infinite Biologics receives $44.5 million Cooperative Agreement award from NIMH centre

RUCDR Infinite Biologics, the world's largest university-based biorepository, received a $44.5 million Cooperative Agreement award from the National Institute of Mental Health earlier this month to support its NIMH Center for Collaborative Genomics Research on Mental Disorders, which provides services to NIMH-funded scientists engaged in genomic research on mental disorders.

28 Jun 2013

Parkland Health Mart Pharmacy honored with McKesson's Pharmacy of the Year award

McKesson Corporation announced that its 2013 Pharmacy of the Year grand prize winner is Parkland Health Mart Pharmacy, located in Desloge, Missouri. Parkland Health Mart Pharmacy was honored in a special awards ceremony during the Opening General Session at the 2013 McKesson ideaShare conference.

28 Jun 2013

UH Eye Institute to use Argus II Retinal Prosthesis System to treat patients with RP

University Hospitals Eye Institute will be one of the first medical centers in the United States to offer the Argus II Retinal Prosthesis System.

28 Jun 2013

Consultation News and Research

Updated United States Public Health Service guidelines for management of occupational exposure to HIV

NSM Insurance Group establishes specialty Behavioral Health, Social Services Unit

Aetna extends help to its members affected by wildfires burning in Oregon

Bariatric procedures can lead to rapid, safe and permanent weight loss in obese patients

Fewer states holding alcohol retailers liable for harms caused by customers who were served illegally

Takeda unbinds Phase 3 study of orteronel in patients with mCRPC that progressed post-chemotherapy

Updated CVD risk audit to help GPs optimise patient management is now available online

Secretary of State for BIS designates LSTM as higher education institution

Researchers receive $10M March of Dimes grant to study causes of premature birth

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Oncodesign receives AAALAC certification for Dijon-based research center

Vanderbilt research program trains community pediatricians to diagnose autism

PrenaTest can be now performed for high risk pregnancies after ninth week

Pharmacyclics submits ibrutinib NDA to FDA for two B-cell malignancies

Agreement expands national presence of Cleveland Clinic Laboratories

Saint Luke's Hospital opens Charles & Barbara Duboc Cardio Health & Wellness Center

NanoViricides submits letter of intent to file Orphan Drug Application with EMA for DengueCide

RUCDR Infinite Biologics receives $44.5 million Cooperative Agreement award from NIMH centre

Parkland Health Mart Pharmacy honored with McKesson's Pharmacy of the Year award

UH Eye Institute to use Argus II Retinal Prosthesis System to treat patients with RP

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News